WESTBOROUGH, Mass. June 30 Joseph B. Bolen, Ph.D., CSO ofMillennium Pharmaceuticals, will chair the Focus on Cancer track IBC LifeSciences Drug Discovery & Development of Innovative Therapeutics Conferenceand Exhibition taking place August 4-7 at the World Trade Center Boston &Seaport Hotel in Boston, MA. The cancer track presentations will focus ontherapies for Hematology, Lung Cancer, Blood Borne Cancers, and ClinicalBiomarkers.
Bolen has confirmed academia speakers including: Kenneth C. Anderson,M.D., Dana Farber Cancer Institute, Harvard Medical School; Bruce E. Johnson,M.D., Dana-Farber Cancer Institute, Harvard Medical School, Brigham andWomen's Hospital; Mark A. Israel, M.D., Dartmouth Medical School; Neal Rosen,M.D., Ph.D., Memorial Sloan-Kettering Cancer Center; Massimo Loda, M.D., DanaFarber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School
Companies also giving technical conference presentations in this cancertrack include Alnylam Pharmaceuticals, Amgen, Inc., ARIAD PharmaceuticalsInc., ArQule, Inc., AstraZeneca R&D Boston, Bristol-Myers Squibb Company,Exelixis Inc, Genzyme Corporation, Infinity Pharmaceuticals, Inc, MerckResearch Laboratories, Novartis Institutes for BioMedical Research, OncoMedPharmaceuticals Inc, The Johnson & Johnson Family of Companies.
Additional conference sessions at Drug Discovery & Development ofInnovative Therapeutics conference include:
-- The Next Generation of Therapeutics: Emerging Biologics, Stem Cells andRNAi
IBC's Drug Discovery & Development of Innovative Therapeutics Conferenceand Exhibition is an international event that covers topics across multipletherapeutic areas. The event includes over 15 presentations from more than200 speakers, 150 exhibitors, 13 interactive round table discussions and 4keynote presentations. For more information please visit www.drugdisc.com.
Complete details on this event can be found at www.drugdisc.com or toreceive a press pass or arrange an interview with a speaker, email Keri Dostieat email@example.com.
About IBC Life Sciences
IBC Life Sciences is the worldwide leader in scientific, technological andbusiness conferences and courses for the life science industry. To developits programs, IBC actively researches the advancements, technologies andtrends impacting and driving the race for new drugs and therapies. No otherorganization can make claim to the breadth and quality that IBC Life Sciencesdelivers in each event giving the company recognition around the globe forquality, service and value. For more information, visit:http://www.IBCLifeSciences.com.-- Cardio-Metabolic Disease Drug Discovery and Development -- Translational Medicine/Research -- Transforming Technologies -- Anti-Infective Drug Discovery and Development -- Neurodegenerative Disease Drug Discovery and Development -- Inflammation in Drug Discovery and Development -- Orphan Diseases: Fast-Tracking Orphan Drugs and Scientific Advances
SOURCE IBC Life Sciences